Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers  by Wilson, Timothy R. et al.
Cancer Cell
ArticleNeuregulin-1-Mediated Autocrine Signaling
Underlies Sensitivity to HER2 Kinase Inhibitors
in a Subset of Human Cancers
Timothy R. Wilson,1,2 Diana Y. Lee,1 Leanne Berry,2 David S. Shames,2 and Jeff Settleman1,2,*
1Massachusetts General Hospital Cancer Center and Harvard Medical School. Building 149, 13th Street, Charlestown, Boston,
MA 02129, USA
2Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
*Correspondence: settleman.jeffrey@gene.com
DOI 10.1016/j.ccr.2011.07.011SUMMARYHER2 kinase inhibitors, such as lapatinib, have demonstrated clinical efficacy in HER2-amplified breast
cancers. By profiling nearly 700 human cancer cell lines, we identified a subset of non-HER2 amplified cancer
cells with striking sensitivity to HER2 kinase inhibition—particularly from head and neck tumors. These cells
were found to depend on a neuregulin-1 (NRG1)-mediated autocrine loop driving HER3 activation, which can
be disrupted by lapatinib. Elevated NRG1 expression and activated HER3 are strongly associated with lapa-
tinib sensitivity in vitro, and these biomarkers were enriched in a subset of primary head and neck cancer
samples. The findings suggest that patients with NRG1-driven tumors lackingHER2 amplification may derive
significant clinical benefit from HER2:HER3-directed therapies.INTRODUCTION
The dependency of tumor cells on a single activated protein or
pathway activity, despite the likely accumulation of numerous
oncogenic mutations, is referred to as ‘‘oncogene addiction’’
(Weinstein et al., 1997), and this phenomenon has been demon-
strated in a variety of murine cancer models that rely on the
sustained expression of the transforming oncogene for tumor
maintenance (Sharma and Settleman, 2007). This reliance on a
single activated oncoprotein implicates a potential ‘‘Achilles’
heel’’ in such cells, which has been successfully exploited by
the discovery and development of anticancer agents that selec-
tively target these critical proteins and associated signaling
pathways to yield clinical benefit in molecularly defined patient
populations. For example, in breast cancer, approximately 25%
of patients demonstrate genomic amplification of HER2, en-
coding the human epidermal growth factor (EGF) receptor
(EGFR)-related kinase, which can be targeted by the HER2
receptor antibody trastuzumab (Slamon et al., 2001), frequentlySignificance
Several mutationally activated kinases are clinically validated
interest in tumor genotyping to prospectively identify patients
testing may not capture all patients who might derive benefit
pathways do not necessarily require mutational activation. W
driven by an autocrine-signaling loop in which the HER3 li
HER2 kinase. In these cases HER2 inhibition effectively bloc
with drug response, suggesting a diagnostic strategy to identif
from established HER2:HER3-targeted therapies.
158 Cancer Cell 20, 158–172, August 16, 2011 ª2011 Elsevier Inc.leading to clinical benefit. Similarly, nonsmall cell lung cancers
(NSCLCs) that harbor activating EGFR kinase domain mutations
are likely to respond to the selective EGFR kinase inhibitors
erlotinib and gefitinib (Sequist and Lynch, 2008).
The HER family of proteins—HER1 (EGFR), HER2, HER3, and
HER4—belongs to the superfamily of receptor tyrosine kinases
(RTKs) (Holbro and Hynes, 2004). Activation of HER receptors
is largely controlled by ligand binding, which induces formation
of homo- and heterodimers, and subsequent activation of kinase
activity. This leads to phosphorylation of specific sites in the
cytoplasmic tail and recruitment of protein adaptors that engage
downstream survival and proliferation pathways (Bose and
Zhang, 2009). Although they share several structural and func-
tional features, there are notable differences among the HER
family members. First, HER2 has no known ligand and has
been proposed to be the ‘‘preferred’’ binding partner for the
other family members due to its open structure (Garrett et al.,
2003). Second, HER3, although catalytically inactive, or weakly
active (Shi et al., 2010), cannot form homodimers but containscancer drug targets. Consequently, there is rapidly growing
most likely to benefit from these agents. However, genomic
from such medicines because oncogenic kinase-mediated
e identified a significant fraction of tested cancer cell lines
gand neuregulin-1 promotes malignancy by engaging the
ks tumor cell growth. We describe a biomarker associated
y patients with non-HER2 amplified tumors that may benefit
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the PI3K survival pathway (Berger et al., 2004; Zhang et al.,
1996). Among the various dimers that can be formed within the
HER family, the HER2:HER3 heterodimer has been suggested
to transduce the strongest signaling response (Tzahar et al.,
1996). Recently, a critical role for HER3 has been demonstrated
in HER2-amplified breast cancer-derived cell lines (Lee-Hoeflich
et al., 2008).
Overexpression or mutational activation of HER proteins may
not be the only mechanisms by which HER signaling pathways
can be engaged in tumor cells and, consequently, impact the
response to pathway-targeted therapeutics. Thus, cancer cells
can produce various EGF-related ligands that result in autocrine
activation of survival and proliferation signals (Salomon et al.,
1995). For example, a recent study demonstrated that autocrine
production of the EGFR ligand amphiregulin is associated with
sensitivity of EGFR wild-type cancer cells to EGFR-targeted
therapies (Yonesaka et al., 2008). Similarly, a RNAi screen
identified HER3 as a therapeutic target in ovarian cancer via
its activation by a neuregulin-1 (NRG1) autocrine loop (Sheng
et al., 2010). In light of these various HER activation mecha-
nisms, several therapeutic strategies have been developed to
inhibit HER-mediated signaling (Hynes and Lane, 2005). These
include antibodies that bind the extracellular domain (ECD) of
HER proteins, such as cetuximab, which binds EGFR, and
trastuzumab, which binds HER2, as well as small molecule
tyrosine kinase inhibitors (TKIs), such as erlotinib, which inhibits
EGFR, and lapatinib, which inhibits EGFR and HER2. Following
successful clinical testing these molecules have been FDA
approved for the treatment of cancer patients. Thus, erlotinib
is used to treat metastatic NSCLC patients that have pro-
gressed on chemotherapy (Smith, 2005), and lapatinib is used
to treat HER2-positive metastatic breast cancer patients that
have progressed on trastuzumab therapy (Medina and Goodin,
2008).
The ability to prospectively identify patients likely to respond
to the various molecularly targeted therapies is critical to their
optimal clinical utility. Fortunately, human tumor-derived cell
lines have proven to be a useful platform in which to identify
such predictive biomarkers associated with oncogene addiction
(Sharma et al., 2010). We have previously described a high-
throughput platform for profiling the sensitivity of human tumor
cell lines to a variety of kinase inhibitors, demonstrating the
ability of this platform to reveal clinically relevant biomarker-
response relationships (McDermott et al., 2007). For example,
we recently described the ability of this approach to establish
ALK (anaplastic lymphoma kinase)-associated chromosomal
translocations as a sensitizing genotype in the context of treat-
ment with a selective ALK inhibitor (McDermott et al., 2008), pro-
mpting successful clinical testing of an ALK inhibitor in genomi-
cally defined lung cancer patients (Kwak et al., 2010).
To date, we have employed this platform to test approximately
700 solid tumor-derived cell lines with a variety of compounds
that correspond to clinically approved cancer drugs, investiga-
tional compounds, or promising preclinical agents. Because
many of these candidate therapeutic compounds hold promise
as effective anticancer drugs, preclinical studies are warranted
to identify molecularly defined subclasses of tumors that can
be used to guide their clinical development Here, we describethe use of this platform to identify a biomarker-defined subset
of tumor cells that demonstrate sensitivity to HER2-targeted
kinase inhibitors that is independent of genomic HER2 status.
RESULTS
A Subset of Non-HER2 Amplified Cancer Cell Lines
Is Sensitive to HER2 Kinase Inhibition
We profiled the sensitivity of 690 cancer cell lines, derived from
multiple tissue types (see Figure S1 available online), to the
investigational irreversible dual EGFR and HER2 TKI HKI-272
(Figure 1A and Table S1). Whereas the vast majority of HKI-
272-treated cell lines were largely treatment refractory, a small
proportion of cell lines exhibited either moderate sensitivity
(12.2%) or extreme sensitivity (1.3%) to HKI-272. The most sen-
sitive cell lines are represented in Figure 1A. To determine the
contribution of EGFRdependency to HKI-272 sensitivity, we per-
formed a parallel analysis of the same cell line panel with the
EGFR-selective TKI erlotinib. As expected, among the HKI-
272-sensitive cell lines, we identified several lines with HER2
gene amplification, such as the UACC-893 and SKBR3 breast
cancer cell lines and the NCI-N87 gastric cancer cell line. We
also identified cell lines that harbor activating EGFR mutations,
such as the NSCLC cell lines: H3255, PC-9, HCC-827, and
PC-14. These EGFR-mutated cells also displayed sensitivity to
erlotinib, indicating that the observed sensitivity of those cells
to HKI-272 was due to EGFR kinase inhibition and not to HER2
kinase inhibition.
In addition to the treatment-sensitive lines that could be
explained by the presence of EGFR or HER2 activation, we
identified an additional subset of HKI-272-sensitive cell lines
that was refractory to erlotinib and does not harbor HER2
or EGFR amplifications or mutations. The single-most HKI-
272-sensitive cell line was the erlotinib-refractory MDA-MB-
175-VII breast cancer cell line, and does not exhibit HER2
amplification. Significantly, this cell line reportedly expresses
a NRG1 fusion protein, as a consequence of a chromosomal
translocation, that results in the aberrant autocrine activation
of HER3 (Schaefer et al., 1997). Other HKI-272-sensitive, erlo-
tinib-refractory cell lines include those derived from skin,
kidney, bone, uterus, and intestine. Notably, this subset was
enriched for cell lines derived from head and neck tumors
(Table S2).
As a complementary approach, we carried out a secondary
screen using the FDA-approved drug lapatinib, a dual EGFR/
HER2 inhibitor, on a panel of 22 cell lines arbitrarily selected
from among 34 of the identified HKI-272-sensitive cell lines
that were also largely erlotinib refractory (as indicated in Fig-
ure 1A). These cells could be categorized into three groups:
sensitive (response below 1 mM), moderately sensitive (response
between 1 and 5 mM), and refractory (no response) (Figure 1B).
IC50 values are listed in Figure 1A. Because lapatinib is report-
edly one of the most selective TKIs developed to date (Bant-
scheff et al., 2007), the lack of complete correlation with the
HKI-272 sensitivity profile observed in the large cell panel is likely
to reflect off-target effects of this irreversible kinase inhibitor.
Collectively, these results indicate that a subset of cancer cell
lines displays sensitivity to HER2 kinase inhibition in the absence
of HER2 gene amplification.Cancer Cell 20, 158–172, August 16, 2011 ª2011 Elsevier Inc. 159
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Figure 1. Large-Scale Cell Line Screening Identifies a Subset of Non-HER2 Amplified Human Cancer Cell Lines Sensitive to HER2 Kinase
Inhibitors
(A) Pie chart representing the cell sensitivity distribution of 690 human solid tumor-derived cell lines when tested for response to the dual EGFR andHER2 inhibitor
HKI-272 (200 nM). The legend corresponds to the fraction of cells remaining (compared to control) following exposure to drug (72 hr). Details for the 8.5% of cell
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NRG1-Driven Cancers Sensitive to HER2 TherapiesLapatinib Sensitivity Is Associated with Elevated pHER3
To establish the molecular mechanism underlying lapatinib
sensitivity in the non-HER2 amplified cell lines, we initially ana-
lyzed the expression of EGFR, HER2, and HER3, as well as the
downstream effectors, AKT and ERK, in the 22 cell lines that
were examined in the secondary screen. As a positive control,
we included the HER2-amplified SKBR3 breast cancer cell line
in the analysis. As anticipated, none of the cell lines analyzed,
other than SKBR3, displayed HER2 amplification (Figure 2A). In
addition basal levels of pEGFR, pHER2, pAKT, and pERK were
not correlated with response to lapatinib. Because previous
reports have demonstrated a critical role for HER3 expression
in HER2-amplified breast cancer cells (Lee-Hoeflich et al.,
2008), we measured HER3 and pHER3 in the cell line panel.
All seven of the highly lapatinib-sensitive cell lines exhibited
elevated pHER3, four of eight of the moderately lapatinib-sensi-
tive cell lines displayed elevated pHER3, and only one of seven
lapatinib-refractory cell lines demonstrated detectable pHER3
(Figure 2A). Thus, elevated pHER3 was well correlated with
response to lapatinib (p = 0.0308; Figure 2B). To determine
whether lapatinib treatment could suppress pHER3 signaling in
the lapatinib-sensitive andmoderately sensitive groups, a subset
of the cell lines was treated with either lapatinib or erlotinib for
2 hr. Lapatinib treatment, but not erlotinib treatment, strongly
suppressed pHER3 as well as downstream AKT activation, sug-
gesting that HER2 kinase, but not EGFR kinase, activity was
driving downstream survival signals in the lapatinib-sensitive
cells, via HER3 (Figure 2C; Figure S2A). In contrast, lapatinib
failed to suppress pAKT in the two refractory cell lines analyzed.
Next, to determine whether the lapatinib-sensitive andmoder-
ately sensitive cell lines (referred to as lapatinib-sensitive cell
lines from this point on) expressing elevated pHER3 are depen-
dent on HER3 expression, we knocked down HER3 using two
independent shRNAs. Lentiviral-mediated infection of CHL-1
cells with shRNAs targeting HER3 successfully depleted HER3
protein (Figure 2D). Significantly, decreasing HER3 in the lapati-
nib-sensitive cell lines demonstrating elevated pHER3 substan-
tially inhibited cell proliferation (Figure 2D; Figure S2B). To con-
trol for potential RNAi-associated off-target effects, we also
knocked down HER3 in the lapatinib-refractory cell line MCF-7,
and no antiproliferative effect was observed. Because pEGFR
and pHER2 were barely detectable in this subset of cell lines,
we employed two complementary approaches to confirm a crit-
ical role for HER2:HER3 heterodimers in signaling to AKT in
these cells. First, we treated CHL-1, FaDu, or SAT cells with tras-
tuzumab (HER2-targeted), pertuzumab (HER2/3-targeted), or a
HER3-directed antibody (Figure 2E; Figures S2C, and S2D). Per-
tuzumab and the HER3-directed antibody suppressed pHER3
and pAKT in these cells. Second, we used shRNAs to knocklines with the highest degree of HKI-272 sensitivity are displayed in the chart to the
sensitivity of these lines to the specific EGFR inhibitor erlotinib (200 nM) is also p
EGFR amplification, where known, is indicated (amp). Red boxes indicate nomuta
Sys, nervous system; Esoph, esophagus; ND, not determined. ‘‘Unexplained sen
largely refractory to erlotinib and displayed a similar or greater HKI-272 respons
(B) Secondary screen using 22 out of a total of 34 arbitrarily selected HKI-272-sens
dual EGFR andHER2 inhibitor, lapatinib (72 hr). The cell lines were categorized into
between 1 and 5 mM), and refractory (did not respond). The IC50 concentration (mM
SEM. See also Figure S1, and Tables S1 and S2.down each of the four HER family members. Because HER4
was undetectable in these cells, we assessed knockdown effi-
ciency in MCF-7 cells (Figure S2E). Knockdown of HER3 sup-
pressed pAKT in CHL-1 and FaDu cells (Figure 2F). Importantly,
knockdown of HER2, but not EGFR or HER4, suppressed
pHER3 and downstream pAKT signaling in these cells. Notably,
the failure to readily detect pHER2 in these cell lines is consistent
with the fact that HER3 has weak kinase activity and is unlikely
to transphosphorylate HER2 in this setting. Consistent with a
requirement for HER3 in the lapatinib-sensitive cell lines, they
were also found to exhibit sensitivity to BEZ235, an inhibitor of
PI-3 kinase, which couples HER3-mediated survival signals to
AKT (Figures S2F and S2G). Together, these results suggest
that HER2:HER3 heterodimers drive cell survival via PI-3 kinase
in a subset of non-HER2 amplified cancer cell lines and that this
pathway can be effectively suppressed by agents that target
HER2 kinase activity.
Lapatinib-Sensitive Cells Secrete a HER3-Activating
Ligand
Activation of HER receptors occurs via ligand binding, resulting
in homodimerization or heterodimerization with other HER
proteins. To determine whether the lapatinib-sensitive cell lines
secrete a HER ligand, we developed an assay using the EFM-
19 breast cancer cell line as a ‘‘reporter’’ of HER3 activation.
EFM-19 cells were selected because they demonstrate low
basal levels of pHER3 but express HER3 and HER2 at levels
similar to those seen in the lapatinib-sensitive MDA-MB-175-
VII cell line (Figure 3A). Exposing EFM-19 cells to serum-free
media conditioned by the MDA-MB-175-VII cell line, which
expresses the NRG1 fusion protein, resulted in the expected
phosphorylation of HER3, demonstrating the utility of this model
to detect the secretion of HER3-activating ligands (Figure 3A).
We next determined whether media conditioned by the lapati-
nib-sensitive, pHER3-positive cell lines could activate HER3 in
the EFM-19 model. Conditioned media from each of the tested
lapatinib-sensitive cell lines activated HER3 in EFM-19 cells (Fig-
ure 3B). As before, pHER2 was undetectable in EFM-19 cells
treated with conditioned media, further supporting the conclu-
sion that HER3 does not transphosphorylate HER2 in this setting
(data not shown). Next, we assessed the ability of conditioned
media from the lapatinib-refractory cells from Figure 2A, and
an extended panel of HKI-272-refractory cell lines (as deter-
mined from the original screen, with a lapatinib IC50 > 5 mM;
data not shown), to activate HER3 in EFM-19 cells. We found
that only 6 of 16 refractory cell lines were able to activate
HER3 in this assay. Furthermore, conditionedmedia from neither
theHER2-amplified SKBR3 cell line nor the EGFR-mutated PC-9
cell line activated HER3 in EFM-19 cells. We next determinedright, which are ranked according to decreasing sensitivity. The corresponding
resented. Green boxes indicate known HER2 amplification or EGFR mutation.
tions, and white boxes indicate unknownmutations. H&N, head and neck; Nerv
sitivity’’ refers to nonmutationally activated cell lines (EGFR or HER2) that were
e than that seen in HER2-amplified SKBR3 cells.
itive, erlotinib-refractory cell lines showing the effect on cell viability of a second
three groups: sensitive (response below 1 mM),moderately sensitive (response
) for each cell line is shown in the final column in (A). Error bars representmean ±
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Figure 2. HER3 Mediates Lapatinib Sensitivity in Non-HER2 Amplified Cancer Cell Lines
(A) Immunoblots indicating levels of pHER2, HER2, pHER3, HER3, pEGFR, EGFR, pAKT, AKT, pERK, and ERK in the lapatinib-sensitive, moderately sensitive,
and refractory cell lines. As a control for HER2 overexpression, the HER2-amplified SKBR3 breast cancer cell line was included.
(B) Box and whisker plot comparing lapatinib sensitivity (cell proliferation, 72 hr) in the detectable pHER3 (n = 13) and nondetectable pHER3 (n = 9)-expressing
cells. Statistical difference between the two groups was assessed using Student’s t test (two-tailed, p = 0.0308). Cell lines belonging to the detectable pHER3
group include: CHL-1, MDA-MB-175-VII, PCI-6A, SAT, FaDu, BHY, DoTC2-4510, CAL27, HSC-3, SNG-M, SN12C, HN, and NCI-H2347. Cell lines belonging to
the pHER3 nondetectable group include: CS1R, LN18, NB69, HuCCT1, DLD-1, DU145, A2.1, NCI-H661, and HSC-2.
(C) Immunoblots showing the effect of acute lapatinib (200 nM) and erlotinib (200 nM) treatment (2 hr) in a panel of lapatinib-sensitive, moderately sensitive, or
refractory cell lines on HER3 phosphorylation and downstream AKT phosphorylation.
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NRG1-Driven Cancers Sensitive to HER2 Therapieswhether activation of HER3 via the addition of conditionedmedia
to EFM-19 cells requires HER2 kinase activity. Conditioned
media from the lapatinib-sensitive cells was added to EFM-19
cells, and cells were cotreated with either lapatinib or erlotinib.
As shown in Figure 3C and Figure S3A, cotreatment with lapati-
nib, but not erlotinib, suppressed HER3 activation in EFM-19
cells. Notably, lapatinib, but not erlotinib, also suppressed HER3
activation in EFM-19 cells treated with conditioned media from
KP4, H2722, and HEC-1 lapatinib-refractory cell lines (Figure 3D).
Further analysis indicated that thesix lapatinib-refractorycell lines
that can activate HER3 in the EFM-19 model do not detectably
express HER3 protein (Figure 3E), and treatment of KP4, HEC-1,
orH2722cellswith lapatinib failed to suppresspAKT (FigureS3B),
indicating that AKT signaling is not driven by HER3 in these cells.
Collectively, these results suggest that the lapatinib-sensitive cell
lines with elevated pHER3 secrete a HER3-activating ligand to
engage an autocrine loop to drive cell survival via HER2 kinase
activity.
Coexpression of NRG1 and HER3 Associates
with Lapatinib Sensitivity
Because the lapatinib-sensitive cell lines all secrete a HER3-
activating ligand, we next assessed their expression of the two
established HER3 ligands, NRG1 and NRG2. NRG1 protein was
significantly elevated in the lapatinib-sensitive lines compared to
seven of the lapatinib-refractory lines, whereas no correlation
was noted with NRG2 expression (Figure 4A). We also analyzed
the expression of NRG1 and NRG2 in a panel of 20 HKI-272-
refractory cell lines (also largely refractory to lapatinib; data not
shown) as determined from the initial screen (Table S1), with a
similar expression profile observed. Of note, all of the lapatinib-
sensitive cell lines expressed HER3 protein; whereas the lapati-
nib-refractory cell lines with elevated NRG1 expression demon-
strated undetectable HER3 protein levels. We next determined
whether increased NRG1 protein was due to increased mRNA.
Overall, we detected relatively high NRG1 mRNA expression in
the lapatinib-sensitivecell lines,withastrongcorrelationobserved
between NRG1 protein and mRNA expression (Figure 4B; R2 =
0.67).Moreover,NRG1andHER3coexpressionwas very strongly
correlated with lapatinib sensitivity (Figure 4C; p < 0.0001).
To confirm that NRG1 was indeed secreted by the lapatinib-
sensitive cells, we analyzed conditioned media from these cells.
The nine tested lapatinib-sensitive cell lines all demonstrated
detectable NRG1 protein in conditioned media, whereas the
lapatinib-refractory EFM-19 and MCF-7 cells, as well as the
HER2-amplified SKBR3 cell line, showed no detectable ex-
pression (Figure 4D). Together, these results indicate that the
non-HER2 amplified lapatinib-sensitive cells secrete NRG1 to
activate HER3 in an autocrine manner. Furthermore, elevated
expression of NRG1 and HER3 was prominently featured in
this lapatinib-sensitive subset of cell lines.(D) Cell viability assay demonstrating suppression of cell proliferation in a pane
shRNAs (5 days). MCF-7 cells were used as a negative control for the effects of RN
RNAi sequences, and shGFP is a control vector. On the right are immunoblots s
a control vector (shGFP) or the HER3-specific shRNAs, 475 and 3293 (72 hr). Er
(E) Immunoblots showing the effect of acute trastuzumab (10 mg/ml), pertuzumab
FaDu, and SAT cells on HER3 phosphorylation and downstream AKT phosphory
(F) Immunoblots showing the expression of EGFR, HER2, pHER3, HER3, pAKT,
HER2, HER3, or HER4 shRNA vectors (72 hr). shGFP represents a control vectoKnockdown of NRG1 Inhibits Cell Proliferation
in Lapatinib-Sensitive Cells
To explore the functional relevance of NRG1 in the lapatinib-
sensitive cell lines, we performed NRG1 knockdown studies.
Four different shRNAs targeting NRG1 successfully decreased
NRG1 protein and mRNA (Figure 5A; Figure S4A). Depleting
NRG1 in the lapatinib-sensitive cells significantly reduced pro-
liferation, whereas depleting NRG1 in MCF-7 or SKBR3 cells
(negative controls) had no detectable effect (Figure 5B; Fig-
ure S4B). To control for potential off-target RNAi effects, we
carried out a rescue experiment in the lapatinib-sensitive mela-
noma cell line CHL-1. CHL-1 cells were transduced with shRNAs
targeting NRG1 in the presence of recombinant human (rh)
NRG1. The addition of rhNRG1 substantially rescued the effects
of knocking down NRG1 in CHL-1 cells (Figure 5C). To further
confirm that NRG1 was indeed the secreted factor that pro-
moted HER3 activation in these cells, we knocked down NRG1
and tested the ability of these cells to produce conditioned
media that activates HER3 in the EFM-19 reporter model. Condi-
tioned media from NRG1-depleted cells failed to activate HER3
in EFM-19 cells compared to shGFP-transduced cells (Fig-
ure 5D; Figure S4C). To verify that NRG1 was depleted from
the media, we collected and concentrated media from NRG1
shRNA-transduced SN-12C cells. Levels of secreted NRG1
were substantially reduced in cells transduced with shRNAs
targeting NRG1 (Figure 5E).
HER2 Kinase Inhibition Suppresses Xenograft Growth
in NRG1 Autocrine Cancer Cell Lines
To extend the cell line findings to an in vivo tumor model, we
carried out xenograft studies using the FaDu head and neck
cancer cell line and the SN-12C renal cell carcinoma cell line.
First, to confirm that lapatinib could suppress pHER3 in vivo,
we implanted FaDu cells subcutaneously in the flanks of nu/nu
mice, and determined that lapatinib treatment (100mg/kg) effec-
tively suppressed pHER3, as well as pHER2, and pAKT activity in
FaDu xenografts (Figure 6A). Next, we assessed the ability of
lapatinib to retard tumor growth. Tumors were allowed to grow
until they reached an average volume of 130 mm3 (Figure 6B),
at which point mice received either lapatinib or vehicle control
every day for 3 weeks. Xenografts of lapatinib-treated mice
grew at a significantly slower rate than xenografts of vehicle
control-treated mice. Lapatinib also suppressed the growth of
SN-12C xenografts, with significant growth only observed
once lapatinib treatment was ceased (day 30) (Figure 6C).
The modest effects of lapatinib probably reflect its inability to
fully suppress pAKT when FaDu cells are grown as xenografts.
Consistent with this notion, it was recently reported that inter-
mittent high-dose lapatinib treatment more robustly inhibited
HER2 activity compared to standard daily dosing (Amin et al.,
2010). To complement the lapatinib findings, and to confirml of lapatinib-sensitive cell lines following lentiviral infection of HER3-specific
Ai. shHER3 475 and shHER3 3293 represent two independent HER3-targeting
howing HER3 protein expression in CHL-1 cells following infection with either
ror bars represent mean ± SEM.
(10 mg/ml), or a HER3-targeted antibody (10 mg/ml) treatment (2 hr) in CHL-1,
lation.
and AKT in CHL-1 and FaDu cells following infection with two different EGFR,
r. See also Figure S2.
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Figure 3. A HER3-Activating Ligand Is Secreted by Non-HER2 Amplified Lapatinib-Sensitive Cell Lines
(A) Left view has immunoblots showing the expression of pHER2, HER2, pHER3, HER3, pAKT, AKT, pERK, and ERK in the HER2-amplified SKBR3, the NRG1-
DOC4 fusion containing MDA-MB-175-VII, and the EFM-19 breast cancer cell lines. Right view is of immunoblots demonstrating HER3 activation (pHER3) in
EFM-19 cells following the addition of media conditioned overnight from the MDA-MB-175-VII cell line.
(B) Immunoblots showing HER3 activation in EFM-19 cells following the addition of conditioned media (CM) from a panel of lapatinib-sensitive (green) and
lapatinib-refractory (red) cell lines (30 min). The effect of conditioned media from the HER2-amplified SKBR3 and the EGFR mutated PC9 cell lines on the
activation of HER3 (pHER3) in EFM-19 cells is also shown.
(C) Immunoblots showing the effects of cotreatment with lapatinib (500 nM) or erlotinib (500 nM) on the ability of CM from the panel of lapatinib-sensitive cell lines
to activate HER3 in EFM-19 cells (30 min).
(D) Immunoblots showing the effects of cotreatment with lapatinib (500 nM) or erlotinib (500 nM) on the ability of CM from KP4, HEC-1, and H2722 lapatinib-
refractory cell lines to activate HER3 (pHER3) in EFM-19 cells (30 min).
(E) Immunoblots showing the levels of pHER3, HER3, pAKT, and AKT in the lapatinib-refractory KP4, HEC-1, H2722, A2.1, NCI-H661, andHSC-2 cell lines. CHL-1
lysate is included as a positive control for pHER3 levels. WCE, whole-cell extract. See also Figure S3.
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Figure 4. NRG1 Is Highly Expressed and Secreted by the Non-HER2 Amplified Lapatinib-Sensitive Cell Lines
(A) Immunoblots showing the expression of NRG1, NRG2, HER3, and ERK in the panel of lapatinib-sensitive (green) cell lines and a panel of lapatinib-refractory
(red) cell lines derived from multiple tissue types. Cell line histology is indicated below the immunoblots. Me, melanoma; K, kidney; C, cervical; H, head and
neck; U, uterus; B, breast; P, pancreatic; G, gastric; E, endometrial; Li, liver; M, mesothelioma; I, intestine; Pr, prostate; L, lung.
(B) Correlation between NRG1 protein and mRNA expression in the panel of lapatinib-sensitive (green squares) and lapatinib-refractory (red triangles) cell lines.
Lapatinib-sensitive cell lines include: CHL-1, PCI-6A, FaDu, CAL27, HSC-3, SAT, SNG-M, SN-12C, and DoTC2-4510. Lapatinib-refractory cell lines include:
EFM-19, MCF-7, MDA-MB-468, KP4, SUIT2, GTL16, HEC-1, ESS-1, H2722, and DV90.
(C) Box and whisker plot comparing lapatinib response (cell proliferation, 72 hr) in the NRG1 and HER3-coexpressing cells (n = 10) compared to the NRG1 or
HER3 negative-expressing cells (n = 21). Statistical difference between the two groups was assessed using Student’s t test (two-tailed, p < 0.0001).
(D) Immunoblot demonstrating secreted NRG1 in the media from the panel of lapatinib-sensitive cell lines. Media from EFM-19, MCF-7, and SKBR3 cells are
included as negative controls.
Cancer Cell
NRG1-Driven Cancers Sensitive to HER2 Therapiesthe suspected role of HER2:HER3 signaling in mediating the
tumorigenic properties of these NRG1-driven cells, we also
determined that treatment of the xenografted tumors with
pertuzumab, a monoclonal antibody that inhibits HER2:HER3
dimerization, similarly suppressed pHER3 as well as tumor
growth (Figure 6B). These results support the potential in vivo
relevance of the cell culture findings.Elevated NRG1 Expression and HER3 Activation
in Primary Head and Neck Cancers
To determine the potential clinical relevance of the observed
NRG1-mediated autocrine lapatinib sensitivity mechanism, we
further explored these biomarker profiles in the setting of
head and neck cancer, the most frequently observed tumor
type demonstrating lapatinib sensitivity beyond HER2-amplifiedCancer Cell 20, 158–172, August 16, 2011 ª2011 Elsevier Inc. 165
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Figure 5. NRG1 Mediates Cell Survival in Non-HER2 Amplified Lapatinib-Sensitive Cell Lines
(A) Immunoblots showing NRG1 protein expression in CHL-1 and SN-12C cell lines following infection with either a control vector (shGFP) or the NRG1-specific
vectors (5 days). The numbers 613, 834, 868, and 923 correspond to four different RNAi sequences.
(B) Cell viability assay demonstrating suppression of cell proliferation in a panel of lapatinib-sensitive cell lines following lentiviral infection of NRG1-specific
shRNAs or a control (shGFP) vector (5 days). MCF-7 cells were used to control for the effects of RNAi. Error bars represent mean ± SEM.
(C) Lentiviral rescue experiment in CHL-1 cells transduced with NRG1 shRNAs for 5 days. Following overnight infection, media was changed, and cells were
treated daily with rhNRG1-b1 (100 ng/ml) as indicated. Error bars represent mean ± SEM.
(D) Left view has immunoblots showing the expression of NRG1 in a panel of the lapatinib-sensitive cell lines following infection with either a control (shGFP) or
NRG1 (834 and 868) shRNA vectors (5 days). WCE, whole-cell extract. Right view is of immunoblots showing the activation of HER3 (pHER3) in EFM-19 cells
following the addition of conditioned media from the panel of lapatinib-sensitive cells on the left (30 min). Twenty-four hours prior, lentiviral-infected cells were
washed, and the media was replaced with unsupplemented media. The volume of conditioned media added to EFM-19 cells was adjusted to control for the
antiproliferative effect observed in the NRG1 shRNA-transduced cells.
(E) Detection of secreted NRG1 in the media from SN-12C cells following lentiviral infection with a control vector (shGFP) or 4 different NRG1 shRNAs; 613, 834,
868, and 923 (5 days). Twenty-four hours prior to collection, the cells were washed and the media replaced with unsupplemented media. See also Figure S4.
Cancer Cell
NRG1-Driven Cancers Sensitive to HER2 Therapiesbreast cancers. Initially, we compared levels of pHER3 and
NRG1 between the five lapatinib-sensitive head and neck caner
cell lines previously described (Figures 2A and 4A) and a set of
five lapatinib-refractory head and neck cancer cell lines that
failed to respond to HKI-272 (Table S1 and Figure S5A). Similar166 Cancer Cell 20, 158–172, August 16, 2011 ª2011 Elsevier Inc.to our previous findings, elevated NRG1 expression and in-
creased pHER3 were observed in the panel of head and
neck cancer-derived lapatinib-sensitive cell lines (Figure 7A).
Significantly, NRG1 expression and pHER3 were undetectable
in the panel of lapatinib-refractory head and neck cancer cell
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Figure 6. HER2 Kinase Inhibition Retards the
Growth of NRG1-Driven Tumor Cells In Vivo
(A) Immunoblots showing suppression of pHER3, pHER2,
and pAKT in FaDu xenografts following treatment with
either lapatinib or pertuzumab.
(B) Tumor growth assay showing the antitumor effect of
lapatinib and pertuzumab on FaDu xenografts. Mice were
treated as stated in the Experimental Procedures. Differ-
ences between the lapatinib or pertuzumab-treated group
and the vehicle control-treated group were calculated
using two-way ANOVA. Error bars represent mean ± SEM.
(C) Tumor growth assay showing the antitumor effect of
lapatinib on SN-12C xenografts. Mice were treated as
stated in the Experimental Procedures. Differences
between the two groups were calculated using two-way
ANOVA. Error bars represent mean ± SEM.
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NRG1-Driven Cancers Sensitive to HER2 Therapieslines. Moreover, NRG1 was undetectable in the conditioned
media of the lapatinib-refractory cell lines (Figure S5B). Consis-
tent with the findings described above, we found that elevated
NRG1, but notHER3, mRNA expression correlated with lapatinib
response (Figure 7B; Figure S5C). Biochemically, lapatinib (or er-
lotinib) failed to suppress pAKT in the lapatinib-refractory head
and neck cancer cell lines, indicating that the HER2 kinase is
not signaling to AKT in these cell lines (Figure S5D).
Next, we assessed NRG1 and HER3 mRNA levels in 29
primary head and neck cancer samples and compared the
expression to the lapatinib-sensitive cell lines and a panel of
17 lapatinib-refractory cell lines (Figure 7C). All of the lapati-
nib-sensitive cell lines demonstrated relatively high levels of
NRG1 mRNA expression, with coexpression of HER3 mRNA
(Figure 7C). Of note, NRG1 mRNA expression was nearly
undetectable in 12 out of 17 lapatinib-refractory cell lines.
Elevated NRG1 mRNA expression was also observed in KP4
and HEC-1 lapatinib-refractory cell lines, which correlated
with NRG1 protein expression (Figure 4A). However, elevated
NRG1mRNA expression was also observed in the ESS-1 endo-
metrial cancer and H2722 mesothelioma cell lines, which failed
to correlate with increased NRG1 protein expression (Figure 4A),
indicating that NRG1 expression may be regulated at the
post-transcriptional level in these cells. Similar to what was
observed at the HER3 protein level (Figure 4A), the lapatinib-
refractory, NRG1-elevated cell lines displayed low levels of
HER3 mRNA. Significantly, we found that 12 out of 29 primary
tumor samples displayed similar elevated levels of NRG1 and
coexpression of HER3 (Figure 7C). Strikingly, 6 primary tumor
samples (13, 17, 22, 24, 25, and 29) showed extremely high
expression levels of NRG1 mRNA as compared to the expres-
sion observed in the lapatinib-sensitive cell lines. Of note, this
biomarker profile was not observed in primary lung cancer
samples, where NRG1 mRNA was barely detectable in the
majority of cases (Figure S5E). We also carried out an immu-Cancer Cell 20, 1noprecipitation (IP)-immunoblot to determine if
the HER3 receptor was detectably activated in
the primary tumor samples. Significantly, we
detected pHER3 in four of ten samples analyzed
(Figure 7D). Importantly, these four samples
(out of five) in this subset analyzed, displayed
at least median expression of NRG1 mRNA.Collectively, these data indicate that a significant proportion of
head and neck tumors may exhibit a dependency on a NRG1-
mediated autocrine loop, and could consequently respond to
HER2:HER3-targeted therapies.
DISCUSSION
The ability to predict a cancer patient’s response to drug treat-
ment based on specific molecular features of their tumor cells
is beginning to dramatically impact the practice of medical
oncology. Thus, the identification of predictive biomarkers in
the form of ‘‘drug-sensitizing’’ oncogenic alleles such as fusion
genes (BCR-ABL and EML4-ALK), activating mutations (EGFR
and BRAF), or genomic amplification (HER2) has been critical
to the successful clinical development of molecularly targeted
drugs that are selectively efficacious in these genomically
defined patient subsets (Sharma and Settleman, 2007). At the
same time, many of these drug targets—the kinases in partic-
ular—may contribute to tumorigenesis despite the absence of
target-associated genomic lesions, possibly pointing to addi-
tional settings in which these same drugs could be clinically
effective. Here, we observed that HER2-directed kinase inhibi-
tors may be effective antitumor agents beyond the context of
HER2 gene amplification, the only clinical setting in which they
are currently employed. We determined that a subset of a very
large panel of tested human cancer cells lines, derived from
multiple tissue types, exhibits a strict dependence on NRG1
secretion that drives HER2:HER3-mediated downstream sur-
vival signals. Of note, this autocrine survival mechanism was
most frequently observed in head and neck carcinomas. In addi-
tion this subset of drug-sensitive cell lines, which do not exhibit
EGFR or HER2 genomic activation, was defined by elevated
NRG1 expression, as well as coexpression of HER3, a biomarker
observed in a significant subset of primary head and neck
tumors. These findings suggest that a molecularly defined58–172, August 16, 2011 ª2011 Elsevier Inc. 167
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Figure 7. A Lapatinib Sensitivity Biomarker Is Observed in Head and Neck Primary Tumors
(A) Immunoblots showing the levels of pHER2, HER2, pHER3, HER3, NRG1, pAKT, and AKT in a panel of lapatinib-sensitive and -refractory head and neck tumor-
derived cell lines.
(B) Box and whisker plot comparing NRG1mRNA expression between the lapatinib-sensitive and lapatinib-refractory head and neck cancer cell lines. Statistical
difference between the two groups was assessed using Student’s t test (two-tailed, p = 0.026).
(C) Quantitative PCR analysis showing the expression of NRG1 and HER3 in head and neck primary tumor samples. As a comparison for expression, lapatinib-
sensitive and -refractory cell lines are included. The blue dashed line represents the median NRG1 expression calculated using the expression from the panel of
lapatinib-sensitive cell lines. Error bars represent mean ± SEM.
(D) Immunoblot showing the constitutive activation of HER3 (pHER3) in a subset of head and neck primary tumor samples. HER3 was immunoprecipitated as
described in the Experimental Procedures and subsequently immunoblotted with antibodies directed against pHER3 andHER3, respectively. See also Figure S5.
Cancer Cell
NRG1-Driven Cancers Sensitive to HER2 Therapiessubset of cancer patients lacking HER2 gene amplification may
benefit from therapy with HER2:HER3-targeted drugs.
Following the clinical success of cetuximab in the treatment of
metastatic head and neck cancer patients, early-phase studies
to assess the potential benefit of lapatinib treatment have
recently been initiated. In a phase I study, lapatinib in combina-168 Cancer Cell 20, 158–172, August 16, 2011 ª2011 Elsevier Inc.tion with chemoradiation revealed an acceptable tolerability
profile, with an objective response rate of 81% observed (Har-
rington et al., 2009). In a phase II study, prolonged tumor stabi-
lization was observed in 36% of patients with malignant salivary
gland tumors (Agulnik et al., 2007). However, in this study only
patients whose tumor stained 2+ for HER2 by IHCwere included.
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Figure 8. Model Depicting the Proposed NRG1-Mediated Autocrine-
Signaling Mechanism
NRG1 secreted by cancer cells in an autocrine manner binds to HER3, re-
sulting in its heterodimerization with HER2. HER2 subsequently phosphory-
lates HER3 resulting in the activation of the PI3K/AKT pathway promoting cell
survival and proliferation. Importantly, transphosphorylation of HER2 is not
required for this signaling cascade. As proposed, this pathway can be inhibited
at multiple steps: first, by preventing NRG1 from binding HER3 using HER3-
targeted antibodies; second, by preventing HER2:HER3 heterodimerization
using a heterodimer-blocking antibody, such as pertuzumab; and finally, by
inhibiting HER2 kinase activity using a HER2 TKI such as lapatinib.
Cancer Cell
NRG1-Driven Cancers Sensitive to HER2 TherapiesUnfortunately, such studies would not be expected to reveal
potential clinical activity in patients whose tumors are driven by
NRG1-mediated autocrine signaling, as would be anticipated
based on our preclinical findings. Another phase I study assess-
ing lapatinib toxicity in patients with solid malignancies demon-
strated stable disease in 29% of patients, with one patient expe-
riencing a complete response (Burris et al., 2009). These results
are consistent with a role for HER2 kinase inhibition beyond the
context of HER2-amplified breast cancer.
The oncogenic RTKs can all potentially be engaged via
elevated expression of their associated ligands, either produced
by tumor stroma or the tumor cells themselves. Such paracrine
or autocrine activation of these receptors, which may be ex-
pressed at relatively low levels on tumor cells, is likely to go
undetected by traditional techniques used to measure receptor
expression or by assessing common receptor-activating muta-
tions that have been found in various tumor types. Our findings
demonstrate that a HER2-mediated autocrine loop drives
a subset of NRG1-overexpressing tumors and may be relevant
to other RTK-mediated oncogenic pathways. We have previ-
ously reported a PDGF (platelet-derived growth factor)-driven
NSCLC cell line that demonstrated striking sensitivity to the
PDGFR TKI sunitinib (McDermott et al., 2009). Similarly, treat-
ment of the KP4 HGF-secreting orthotopic model of pancreatic
cancer with a monoclonal antibody targeting Met (MetMAb)
retarded xenograft growth resulting in a substantial survival
benefit (Jin et al., 2008). Further clinical studies are warranted
to substantiate these preclinical observations.
The dynamic range of NRG1 mRNA expression observed in
the cell line models and tumor samples we analyzed potentially
reflects the contribution of both genetic and epigenetic regula-
tory mechanisms. To date, mutational activation of NRG1 has
only been documented in a single example—the NRG1-DOC4
fusion protein, resulting from chromosomal translocation, dis-
covered in the MDA-MB-175VII breast cancer cell line (Schaefer
et al., 1997). Of note, the 8p chromosomal arm, where the NRG1
gene resides, has been shown to undergo rearrangements in
a significant proportion of breast cancer cell lines (Huang et al.,
2004; Pole et al., 2006). In addition chromosomal breaks within
this region were discovered in 6% of primary breast tumors,
the majority of which were HER2-low tumors. The functional
significance of the potential fusion proteins observed in these
studies has yet to be demonstrated but highlights the potentially
complex nature of NRG1mRNA regulation. In addition methyla-
tion of the NRG1 transcriptional promoter site has also been
shown to negatively regulate mRNA expression in breast cancer
cell lines, with a correlation noted in primary tumor samples
(Chua et al., 2009). This may also explain the differences we
observed in our cell line models and tumor samples.
Expression of the EGFR family ligands has been well estab-
lished in certain epithelial-derived cancers, especially those de-
rived from the colon, breast, lung, and ovary (Normanno et al.,
2006;Yotsumotoet al., 2009). TheHER familyof ligands, including
EGF, transforming growth factor a, amphiregulin, betacellulin,
heparin-binding-EGF, and NRG1, has been previously shown to
be expressed to various levels in a panel of head and neck cancer
cell lines (O-Charoenrat et al., 2000; O-Charoenrat et al., 2002). In
those studies treatment with exogenous HER family ligands led
to an increase in mRNA expression of the corresponding ligand-encoding genes, most notably for heparin-binding EGF and
NRG1, implicating an autocrine induction of ligand. In addition
Yonesaka et al. (2008) demonstrated that autocrine production
of amphiregulin in EGFR wild-type lung and head and neck
cancer cell lines is associatedwith sensitivity to cetuximab. These
results present further possible therapeutic strategies to inhibit
NRG1, and other EGFR ligand-mediated autocrine signals.
Thus, neutralizing antibodies that disrupt ligand binding may be
efficacious at multiple levels in inhibiting the autocrine signal.
In summary our findings suggest that a patient subpopula-
tion defined by elevated NRG1 expression, and coexpression
and activation of HER3, may derive clinical benefit from
HER2:HER3-targeted therapies such as lapatinib (Figure 8).
Thus, the initiation of a clinical trial in a genomically defined
patient subset, most probably in the setting of head and neck
carcinoma, is warranted to assess these preclinical findings.
The observations also highlight the potential importance of iden-
tifying nonmutationally driven RTK dependencies in human
tumors to inform biomarker strategies for clinical development
of selective kinase inhibitors.
EXPERIMENTAL PROCEDURES
Human Cancer Cell Lines and High-Throughput Tumor Cell Line
Screening
Human cancer cell lines were obtained and tested for sensitivity using an auto-
mated platform as previously described (McDermott et al., 2007). Cell lines
were maintained at 37C in a humidified atmosphere at 5% CO2 and grown
in RPMI 1640 or DMEM/F12 growth media (GIBCO) supplemented with 10%
fetal bovine serum (GIBCO), 50 U/ml penicillin, and 50 mg/ml streptomycin
(GIBCO).
Cell Viability Assays
Cell viability was assessed using the nucleic acid stain SYTO 60 (Invitrogen).
Cells (3000 per well) were seeded into 96-well plates, allowed to adhere over-
night, and exposed to a range of drug concentrations. After 72 hr, cells were
fixed in 4% formaldehyde, stained with SYTO 60, and cell viability wasCancer Cell 20, 158–172, August 16, 2011 ª2011 Elsevier Inc. 169
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reader (excitation 630 nm, emission 695 nm; Molecular Devices). The fraction
of control was calculated by dividing the fluorescence obtained from the
drug-treated cells by the fluorescence obtained from the control (no drug)-
treated cells.
Reagents
HKI-272 was obtained from Wyeth Pharmaceuticals. Lapatinib and erlotinib
were purchased from LC Laboratories. rhNRG1-b1 was purchased from
R&D Systems. Pertuzumab, trastuzumab, and the HER3-targeted antibody
were produced at Genentech. The HER3-directed antibody was selected
from a human phage-displayed antibody library with synthetic diversity in
the selected complementarity determining regions. It was obtained by pan-
ning on immobilized HER3 ECD (HER3-ECD-Fc fusion protein comprising
amino acids 1–621 fused to the Fc domain of human IgG) as described previ-
ously (Lee et al., 2004). The antibody blocks the binding of ligand (NRG1) to
HER3.
Immunoblotting
Cell lysates were harvested using Nonidet-P40 lysis buffer, supplemented with
Halt protease and phosphatase inhibitor cocktail (Thermo Scientific), and
immunodetection of proteins was carried out using standard protocols. The
phospho-EGFR (#2236), phospho-HER2 (#2247), HER2 (#2242), phospho-
HER3 (Y1289; #4791), AKT (#9272), phospho-ERK (T202/Y204; #9101), ERK
(#9102), and HER4 (#4795) antibodies were purchased from Cell Signaling
Technology. Antibodies to HER3 (SC-285), NRG1 (SC-28916), NRG2 (SC-
67001), and EGFR (SC-03) were purchased from Santa Cruz Biotechnology.
Phospho-AKT (S473; #44-621G) antibody was purchased from Invitrogen.
GAPDH (MAB374) antibody was purchased from Chemicon. Densitometry
was carried out using ImageJ software.
Detection of Secreted NRG1
Cells were grown to approximately 80% confluency on a 10 cm dish in normal
growth media, washed once in PBS, and serum starved in 10 ml unsupple-
mented RPMI 1640 or DMEM/F12 growth media as appropriate. Following
overnight incubation, media was harvested, and cell debris was pelleted
at 1500 rpm for 5 min. The conditioned media was then concentrated using
Millipore Amicon Ultra (3K) centrifugal filters at 4000 3 g for 40 min. The
concentrate was transferred to a 1.5 ml ultracentrifuge tube, and one-third
the volume of 43 Sample buffer was added and boiled at 95C for 5 min to
denature any proteins. A total of 20 ml of sample was immunoblotted using
standard techniques. Secreted NRG1 was detected using MAB377 mono-
clonal antibody from R&D Systems.
Lentiviral shRNA Studies
shRNA constructs were obtained from the Broad RNAi consortium, and the
sequences are shown in Supplemental Experimental Procedures. Lentivirus
production was carried out in 293T cells as previously described (Moffat
et al., 2006). For knockdown studies cells were plated in 96-well (3000 cells
per well) or 6-well dishes (2 3 105 cells per well). Following adherence over-
night, cells were spin infected with lentivirus or control virus in the presence
of polybrene (hexadimethrine bromide; Sigma-Aldrich) at 1200 3 g for
75 min at 32C. Twenty-four hours postinfection, media was replaced with
regular growth media. Depending on the experiment, cells were harvested
3 or 5 days post-lentiviral infection for protein lysates, RNA lysates, or cell
viability, which was assayed using SYTO 60 nucleic acid stain as described.
Quantitative PCR Analysis
RNA was extracted from cells using the RNeasy kit (QIAGEN), and 1 mg RNA
was reverse transcribed using the high-capacity RNA-to-cDNA kit (Applied
Biosystems) according to manufacturer’s instructions. The amount of ampli-
con was determined using the Applied Biosystems 7500 quantitative PCR
system using SYBR green as the fluorescence reporter. Each sample was
normalized to the housekeeping gene GAPDH. All samples were analyzed in
triplicate, and the relative expression was determined. Primer sequences are
listed in Supplemental Experimental Procedures.170 Cancer Cell 20, 158–172, August 16, 2011 ª2011 Elsevier Inc.Xenograft Studies
All procedures involving animals were approved by Piedmont’s Research
Center’s Institutional Animal Care and Use Committee (IACUC) and carried
out in an AAALAC (Association for the Assessment and Accreditation of Labo-
ratory Animal Care) accredited facility. FaDu tumor xenografts were grown in
athymic nude mice from Harlan (nu/nu). On the day of implantation, 5 3 106
FaDu cells were injected subcutaneously into the flank of 8-week-old mice.
Tumors were allowed to grow until they reached a size of 88–172 mm3, at
which point mice were randomized into three groups of ten mice each. One
group of animals was treated by oral gavage with lapatinib at 100 mg/kg for
21 days. A second group of animals was treated by intraperitoneal injection
with pertuzumab at 50 mg/kg on day 0 and 25 mg/kg on days 7 and 14. The
final group of animals was treated with vehicles of both agents. An additional
three animals per group were treated for 2 days and then sacrificed for tumor
collection. For the SN-12C xenograft model, 1 3 107 SN-12C cells were
injected subcutaneously into the flank of 8-week-old mice, and tumors were
allowed to grow until they reached a size of 108–196 mm3. Mice were random-
ized into two groups of eight mice each, with one group of animals receiving
lapatinib (100mg/kg) by oral gavage for 30 days, and the other group receiving
vehicle control. Tumor sizes and body weights were measured twice weekly
over the course of treatment.
Tissue Samples
Primary human tumor samples with appropriate IRB approval and patient-
informed consent were obtained from commercial sources. The human tissue
samples used in the study were deidentified (double coded) prior to their use,
and hence, the study using these samples is not considered human subject
research under theU.S. Department of Human andHealth Services regulations
and related guidance (45 CFR, Part 46). The head and neck squamous cell
carcinoma tumors were from Asterand. The NSCLC tumor specimens, which
were adenocarcinomas, were from Asterand and ProteoGenex. For RNA
extraction, tissue sections were submerged in 300 ml RLT buffer (QIAGEN)
and homogenized using a handheld homogenizer (Polytron) and extracted
using TRIzol (Invitrogen), as per the manufacturer’s instructions. cDNA was
generated using the High-Capacity Reverse Transcription Kit (Applied Biosys-
tems). For IP, 2 mg of NP-40 lysed tissue sample was incubated overnight with
5 mg HER3 antibody and protein G. After three washes, the samples were
eluted with western sample buffer, boiled at 95C for 5 min, and immunoblot-
ted as described above.
Statistical Analysis
Box and whisker plots were carried out to compare the differences between
two groups of cell lines. The line indicates themedian value, the box represents
the upper and lower quartile, and the whiskers represent the lowest and
highest value. Differences between the two groups were determined using
Student’s t test.
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